CSTLCastle Biosciences, Inc.

$805M

Q3 2025 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$83M-3.2% YoY

Gross Profit

$64M77.5% margin

Operating Income

-$7M-8.2% margin

Net Income

-$501,000-0.6% margin

EPS (Diluted)

$-0.02

QoQ Revenue Growth

-3.6%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$8M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$563M

Total Liabilities

$96M

Stockholders' Equity

$467M

Cash & Equivalents

$86M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$83M	$86M	-3.2%
Gross Profit	$64M	$70M	-8.3%
Operating Income	-$7M	$5M	-234.0%
Net Income	-$501,000	$2M	-122.1%

Revenue Segments

Dermatologic

$49M100%

CSTL Q3 2025 Earnings — Castle Biosciences, Inc. Revenue & Financial Results | Market Cap Arena